MLM Biologics, Inc. appears in FDA device records as the applicant for epi-ConneKt™ Wound Matrix under K260530, a Traditional 510(k) received on February 17, 2026 and decided on October 15, 2026 with a Substantially Equivalent decision. The filing carries product code KGN and lists an Alachua, Florida address. Separately, the company’s own published documentation describes bio-ConneKt® Wound Matrix, a collagen-based dressing made from reconstituted equine-tendon collagen. The two product names appear in different document sets, and the available records do not state how they relate. [1][3][4]

The FDA filing record

The 510(k) record for K260530 names MLM Biologics, Inc. as applicant, with a device name of epi-ConneKt™ Wound Matrix and a decision description of Substantially Equivalent. The record shows a Traditional clearance type, a third-party review flag of N, and a summary statement. The openFDA device entry associates product code KGN with the device name “Wound Dressing With Animal-Derived Material(S)” and a device class of U. The filing address is 13700 Progress Blvd., Alachua, FL 32615; a filing address is not evidence of a headquarters location. [1]

The linked collection for this company, as of November 20, 2026, contains one 510(k) record, and that single record carries a Substantially Equivalent decision. The record sample contains the same one entry, K260530, so the sample and the full collection coincide at this snapshot. These counts describe the linked filings retrieved at that date and do not represent total company sales, total portfolio or safety performance. [1]

bio-ConneKt® Wound Matrix as documented

The package insert describes bio-ConneKt® Wound Matrix as a sterile, conformable and porous wound dressing made of reconstituted collagen derived from equine tendon, chemically crosslinked to resist enzymatic degradation. It is provided sterile for single use, and the product is exposed to E-beam irradiation at a minimum of 25 kGy. The insert states that federal law restricts the product to sale by or on the order of a physician. [3]

The insert lists the manufacturer at 13700 Progress Boulevard, Alachua, FL 32615, and states that the product is “Exclusively Manufactured for Sale in the USA for” BioWound Solutions, Inc. of Las Vegas, Nevada. That wording identifies BioWound Solutions as the party for whom the product is manufactured, while the manufacturer is listed separately at the Alachua address. The insert carries revision PN-20100-H Rev. 2026/04. [3]

The company’s product page describes bio-ConneKt® Wound Matrix as a collagen-based wound dressing for local management of moderately to heavily exuding wounds, indicated for use wherever there is a breach of the skin. The page lists wound types where the product has been used, including partial and full thickness wounds, pressure sores and ulcers, venous and diabetic ulcers, trauma wounds and surgical wounds. The page also shows product sizing entries such as 6cm x 7cm configurations. [4]

Company statements and published materials

MLM Biologics’ website describes the company as a Delaware C-Corp and presents bio-ConneKt® Wound Matrix as an FDA-cleared, sterile product produced in an ISO-certified facility. The site links to an ISO 13485 certificate, a quality policy, a summary statement, a package insert and reimbursement information, and lists contact details at 13700 Progress Blvd., Alachua, FL 32615. These are company-published claims attributed to MLM Biologics. [2]

A company capabilities statement frames bio-ConneKt® Wound Matrix as an advanced wound care scaffold and describes a proprietary manufacturing technology, stating that the product is wound vac compatible and sits in the High Tier reimbursement bucket through CMS. The same document refers to use in military clinical settings. An administrators page describes the product as FDA-cleared and the company as a Gainesville, FL based medical device company, and links to a clearance letter identified as K140456. [5][7]

What the records do not establish

The available documents do not state a corporate parent, ownership structure or customer list, and no clinical outcome data are presented here. The relationship between epi-ConneKt™ Wound Matrix in K260530 and bio-ConneKt® Wound Matrix in the company’s published materials is not described in these records. The K140456 clearance letter is referenced by link on the administrators page but its contents are not part of the numbered sources, so its scope is unknown. [1][3][7]